Lunai Bioworks (LNAI) EBIT Margin (2013 - 2026)

Lunai Bioworks (LNAI) posted quarterly EBIT Margin of 7054.05% for Q1 2026, up 97.43% quarter-over-quarter from 274996.31% in Q2 2016.

Lunai Bioworks (LNAI) EBIT Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' EBIT Margin history runs 3 years deep, the most recent figure standing at 7054.05% for Q1 2026.

In Q1 2026, EBIT Margin changed N/A year-over-year to 7054.05%; the TTM figure through Mar 2026 stood at 156672.97% (changed N/A YoY), while the FY2016 annual figure was 4959.04%, changed N/A from the prior year.
EBIT Margin for Q1 2026 stood at 7054.05%, up from 274996.31% in the prior quarter.
The five-year high for EBIT Margin was 7054.05% in Q1 2026, with the low at 7054.05% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-7,054.05%

Download Data